Long-term disease management of patients with coronary disease by cardiac rehabilitation program staff

Journal of Cardiopulmonary Rehabilitation and Prevention

Volumn 28, Issue 3, 2008, Pages 180-186

  Squires, Ray W ^a   Montero Gomez, Aura ^b   Allison, Thomas G ^a   Thomas, Randal J ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSIDAD DEL ZULIA   (Venezuela)

Author keywords

Cardiac rehabilitation; Long term disease management

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BODY MASS; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; DIASTOLIC BLOOD PRESSURE; DRUG UTILIZATION; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HEALTH EDUCATION; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PROTECTION; HEART REHABILITATION; HOME CARE; HUMAN; KINESIOTHERAPY; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTPATIENT CARE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SECONDARY PREVENTION; SEX RATIO; SMOKING; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; DISEASE MANAGEMENT; HEALTH CARE QUALITY; REHABILITATION CENTER; RISK FACTOR; TIME; TREATMENT OUTCOME;

AGED; CORONARY ARTERY DISEASE; DISEASE MANAGEMENT; EXERCISE THERAPY; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; PROGRAM EVALUATION; REHABILITATION CENTERS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 53449093999     PISSN: 19327501     EISSN: 1932751X     Source Type: Journal    
DOI: 10.1097/01.HCR.0000320068.35728.12     Document Type: Article

References (18)

1. Ferguson EE, Ades PA. The treatment of dyslipidemia in outpatient cardiac rehabilitation programs. Card Rehabil Medi Director's Newsl. AACVPR 2006;1(3):1-4.
2. Fletcher B, Berra K, Ades P, et al. Managing abnormal blood lipids: a collaborative approach. Circulation. 2005;112:3184-3209.
3. Osterberg L, Blaschke T. Drug therapy: adherence to medication. NEJM. 2005;353:487-497.
4. Minnesota Department of Health. Qual Care Initiative. http://www.health.state.mn.us./healthinfo/qcare.html. Accessed October 5, 2007.
5. Squires RW, Gau GT. Cardiac rehabilitation and cardiovascular health enhancement. In: Brandenburg RO, Fuster V, Giuliani ER, McGoon DC, eds. Cardiology: Fundamentals and Practice. Chicago, IL: Year Book Medical Publishers; 1987:1944-1960.
6. Haskell WL, Alderman EL, Fair JM, et al. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease: the Stanford Coronary Risk Intervention Project (SCRIP). Circulation. 1994;89:975-990.
7. DeBusk RF, Houston Miller N, Superko HR, et al. A case-management system for coronary risk factor modification after acute myocardial infarction. Ann Intern Med. 1994;120:721-729.
8. Krumholz HM, Currie PM, Riegel B, et al. A taxonomy for disease management: a scientific statement from the American Heart Association disease management taxonomy group. Circulation. 2006;114:1432-1445.
9. Smith SC, Blair SN, Bonow RO, et al. AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease. Circulation. 2001;104:1577-1579.
10. Arias E, Smith BL. Deaths: Preliminary Data for 2001. National Vital Statistics Reports. Atlanta, GA: Department of Health and Human Services, Centers for Disease Control and Prevention, National Centers for Health Statistics, and the National Vital Statistics System; 2003:51:1-48.
11. Lear SA, Ignaszewski A, Linden W, et al. A randomized controlled trial of an extensive lifestyle management intervention (ELMI) following cardiac rehabilitation: study design and baseline data. Curr Control Trials Cardiovasc Med. 2002;3:9-23.
12. Lear SA, Ignaszewski A, Linden W, et al. The extensive lifestyle management intervention (ELMI) following cardiac rehabilitation trial. Eur Heart J. 2003;24:1920-1927.
13. The Vestfold Heartcare Study Group. Influence on lifestyle measures and five-year coronary risk by a comprehensive lifestyle intervention programme in patients with coronary heart disease. Eur J Cardiovasc Prev Rehabil. 2003:10:429-437.
14. Reid RD, Dafoe WA, Morrin L, et al. Impact of program duration and contact frequency on efficacy and cost of cardiac rehabilitation: results of a randomized trial. Am Heart J. 2005;149:862-868.
15. Giannuzzi P, Temporelli PL, Maugeri FS, et al. Global secondary prevention strategies to limit event recurrence after myocardial infarction: the GOSPEL study. a trial from the Italian Cardiac Rehabilitation Network: final results. Circulation. 2006;114:II-852.
16. Murchie P, Campbell NC, Ritchie LD, et al. Secondary prevention clinics for coronary heart disease: four year follow up of a randomized controlled trial in primary care. Br Med J. 2003;326:84-87.
17. Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503-1516.
18. Witt BJ, Jacobsen SJ, Weston SA, et al. Cardiac rehabilitation after myocardial infarction in the community. J Am Coll Cardiol. 2004;44:988-996.